CCK and Anxiety: Validation of the efficacy of the lead CCK-BR scFv antibodies for the reduction of hypersensitivity, anxiety-, and depression-like behaviors was investigated in a chronic trigeminal neuropathic pain model in mice persisting 3–4 months.